HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

hemoglobin Heraklion

Subscribe to New Research on hemoglobin Heraklion

Share|Follow on Twitter

deletion of CCC between codons 36 and 37; results in loss of a proline residue

Also Known As:

Hb Heraklion

Networked: 2 relevant articles (0 outcomes, 0 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 58287
  - Blood Proteins: 3668
    - Hemoglobins: 13018
      - Abnormal Hemoglobins: 92
        hemoglobin Heraklion: 2
  - Hemeproteins: 109
    - Globins: 985
      - Hemoglobins: 13018
        Abnormal Hemoglobins: 92
        hemoglobin Heraklion: 2

Experts

1.	Tsilimigaki, Amalia: 1 article (01/2008)
2.	Traeger-Synodinos, Joanne: 1 article (01/2008)
3.	Stamoulakatou, Alexandra: 1 article (01/2008)
4.	Papassotiriou, Ioannis: 1 article (01/2008)
5.	Metaxotou-Mavrommati, Anna: 1 article (01/2008)
6.	Liapi, Dimitra: 1 article (01/2008)
7.	Kanavakis, Emmanuel: 1 article (01/2008)
8.	Kampourakis, Dimitrios: 1 article (01/2008)
9.	Douna, Varvara: 1 article (01/2008)
10.	Vrettou, C: 1 article (08/2000)

Related Diseases

1.	alpha-Thalassemia 01/01/2008 - "In all four cases (two unrelated children and two siblings), DNA analysis identified common alpha(+)-thalassemia (alpha(+)-thal) mutations in trans to the in frame 3 bp deletion (-CCC) on the alpha1-globin gene between codons 36 and 37, which has previously been reported as Hb Heraklion in a single Greek case. " 01/01/2008 - "Further identification of the hyperunstable alpha-globin chain variant Hb Heraklion [codons 36/37 (-CCC); Pro-->0 (alpha1)] in Greek cases with co-inherited alpha+-thalassemia mutations." 08/01/2000 - "In a child with clinical and hematological features consistent with beta-thalassemia intermedia, DNA analysis excluded any beta-globin gene mutations but characterized a novel deletion cd37(C2)Pro>0 (Hb Heraklion) in the alpha1 globin gene, in trans to a common Mediterranean nondeletion alpha-thalassemia mutation (alpha(Hph)alpha). " Order ALL the reference details at left...
2.	beta-Thalassemia (Cooley's Anemia) 08/01/2000 - "In a child with clinical and hematological features consistent with beta-thalassemia intermedia, DNA analysis excluded any beta-globin gene mutations but characterized a novel deletion cd37(C2)Pro>0 (Hb Heraklion) in the alpha1 globin gene, in trans to a common Mediterranean nondeletion alpha-thalassemia mutation (alpha(Hph)alpha). " Order ALL the reference details at left...
3.	Hemoglobinopathies 08/01/2000 - "Distinct phenotypic expression associated with a new hyperunstable alpha globin variant (Hb heraklion, alpha1cd37(C2)Pro>0): comparison to other alpha-thalassemic hemoglobinopathies." Order ALL the reference details at left...

Related Drugs and Biologics

1.	alpha-Globins
2.	DNA (Deoxyribonucleic Acid)
3.	beta-Globins (beta Globin)
4.	Globins
5.	Codon (Codons)
6.	Carbon Monoxide

blog comments powered by Disqus

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>